Batikan has this disease.
Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system. In the United States, between 7,500 and 8,000 diagnoses of testicular cancer are made each year. In the UK, approximately 2,000 men are diagnosed each year, and over his lifetime, a man's risk of testicular cancer is roughly 1 in 200 (0.4%). It is the most common cancer in males aged 20–39 years, the period of peak incidence, and is rarely seen before the age of 15 years. Testicular cancer has one of the highest cure rates of all cancers: If the cancer hasn’t spread outside the testicle, the 5-year relative survival rate is 99%. Even if the cancer has grown into nearby structures or has spread to nearby lymph nodes, the rate is 96%. If it has spread to organs or lymph nodes away from the tumor, the 5-year relative survival rate is around 74%. (metastasized). Even for the relatively few cases in which malignant cancer has spread widely, modern chemotherapy offers a cure rate of at least 80%. Not all lumps on the testicles are tumors, and not all tumors are malignant (cancerous). There are many other conditions, such as testicular microlithiasis, epididymal cysts, and appendix testis (hydatid of Morgagni), which may be painful but are non-cancerous. Contents [hide] 1 Signs and symptoms2 Genetic defects3 Diagnosis3.1 Staging3.2 Classification4 Treatment4.1 Initial treatment (orchiectomy)4.2 Retroperitoneal Lymph Node Dissection (RPLND)4.3 Adjuvant treatment4.4 Radiation therapy4.5 Chemotherapy4.5.1 Non-seminoma4.5.2 Seminoma5 Prognosis5.1 Surveillance5.2 Fertility6 Epidemiology7 In other animals8 References9 External linksSigns and symptomsOne of the first signs of testicular cancer is often a lump or swelling in the testes. The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening for testicular cancer in asymptomatic adolescent and adults including routine testicular self-exams. However, the American Cancer Society suggests that some men should examine their testicles monthly, especially if they have a family history of cancer, and the American Urological Association recommends monthly testicular self examinations for all young men. Symptoms may also include one or more of the following: a lump in one testis which may or may not be painfulsharp pain or a dull ache in the lower abdomen or scrotuma feeling often described as "heaviness" in the scrotumbreast enlargement (gynecomastia) from hormonal effects of β-hCGlow back pain (lumbago) tumor spread to the lymph nodes along the backIt is not very common for testicular cancer to spread to other organs, apart from the lungs. However, if it has, the following symptoms may be present: shortness of breath (dyspnea), cough or coughing up blood (hemoptysis) from metastatic spread to the lungsa lump in the neck due to metastases to the lymph nodesGenetic defectsMost testicular germ cell tumors have too many chromosomes, and most often they are triploid to tetraploid. An isochromosome 12p (the short arm of chromosome 12 on both sides of the same centromere) is present in about 80% of the testicular cancers, and also the other cancers usually have extra material from this chromosome arm through other mechanisms of genomic amplification. Diagnosis This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2014) Micrograph (high magnification) of a seminoma. H&E stain.The main way testicular cancer is diagnosed is via a lump or mass inside the testis. More generally, if a young adult or adolescent has a single enlarged testicle, which may or may not be painful, this should give doctors reason to suspect testicular cancer. Other conditions may also have symptoms similar to testicular cancer: Epididymitis or epididymoorchitisHematoceleVaricoceleIncorrect or mistaken diagnosis can delay access to appropriate treatment; this is thought to occur in up to 25% of cases The nature of any palpated lump in the scrotum is often evaluated by scrotal ultrasound, which can determine exact location, size, and some characteristics of the lump, such as cystic vs solid, uniform vs heterogeneous, sharply circumscribed or poorly defined. The extent of the disease is evaluated by CT scans, which are used to locate metastases. The differential diagnosis of testicular cancer requires examining the histology of tissue obtained from an inguinal orchiectomy - that is, surgical excision of the entire testis along with attached structures (epididymis and spermatic cord). A biopsy should not be performed, as it raises the risk of spreading cancer cells into the scrotum. Inguinal orchiectomy is the preferred method because it lowers the risk of cancer cells escaping. This is because the lymphatic system of the scrotum, through which white blood cells (and, potentially, cancer cells) flow in and out, links to the lower extremities, while that of the testicle links to the back of the abdominal cavity (the retroperitoneum). A transscrotal biopsy or orchiectomy will potentially leave cancer cells in the scrotum and create two routes for cancer cells to spread, while in an inguinal orchiectomy only the retroperitoneal route exists. Blood tests are also used to identify and measure tumor markers (usually proteins present in the bloodstream) that are specific to testicular cancer. AFP alpha1 feto protein, Beta-HCG, and LDH are the typical markers used to identify testicular cancer. A pregnancy test may be used to identify high levels of Beta-HCG, however the first sign of testicular cancer is normally a lump. Note that only about 25% of seminomas have elevated Beta-HCG, so a pregnancy test cannot be use to rule out testicular cancer. StagingAfter removal, the testicle is fixed with Bouin's solution because it better conserves some morphological details such as nuclear conformation. Then the testicular tumor is staged by a pathologist according to the TNM Classification of Malignant Tumors as published in the AJCC Cancer Staging Manual. Testicular cancer is categorized as being in one of three stages (which have subclassifications). The size of the tumor in the testis is irrelevant to staging. In broad terms, testicular cancer is staged as follows: Stage I: the cancer remains localized to the testis.Stage II: the cancer involves the testis and metastasis to retroperitoneal and/or Paraaortic lymph nodes (lymph nodes below the diaphragm).Stage III: the cancer involves the testis and metastasis beyond the retroperitoneal and Paraaortic lymph nodes. Stage 3 is further subdivided into non-bulky stage 3 and bulky stage 3.Further information on the detailed staging system is available on the website of the American Cancer Society. ClassificationAlthough testicular cancer can be derived from any cell type found in the testicles, more than 95% of testicular cancers are germ cell tumors. Most of the remaining 5% are sex cord-gonadal stromal tumours derived from Leydig cells or Sertoli cells. Correct diagnosis is necessary to ensure the most effective and appropriate treatment. To some extent, this can be done via blood tests for tumor markers, but definitive diagnosis requires examination of the histology of a specimen by a pathologist. Most pathologists use the World Health Organization classification system for testicular tumours: Germ cell tumoursPrecursor lesionsIntratubular germ cell neoplasiaUnclassified type (carcinoma in situ)Specified typesTumours of one histologic type (pure forms)SeminomaVariant - Seminoma with syncytiotrophoblastic cellsSpermatocytic seminomaVariant - spermatocytic seminoma with sarcomaEmbryonal carcinomaYolk sac tumourTrophoblastic tumoursChoriocarcinomaVariant - monophasic choriocarcinomaPlacental site trophoblastic tumourCystic trophoblastic tumourTeratomaVariant - Dermoid cystVariant - Epidermoid cystVariant - Monodermal teratoma (Carcinoid, Primitive neuroectodermal tumour (PNET), Nephroblastoma-like tumor, others.Variant - Teratomic with somatic-type malignancyTumours of more than one histologic type (mixed forms)Embryonal carcinoma and teratomaTeratoma and seminomaChoriocarcinoma and teratoma.embryonal carcinomaOthersSex cord/Gonadal stromal tumoursLeydig cell tumourSertoli cell tumourLipid rich variantScleriosing variantLarge cell calcifying variantIntratubular sertoli cell neoplasia in Peutz-Jeghers syndromeGranulosa cell tumourAdult typeJuvenile typeThecoma Fibroma GroupThecomaFibromaSex cord/gonadal stromal tunour - incompletely differentiatedSex cord/gonadal stromal tumour - mixed typesMixed Germ Cell and Sex Cord/Gonadal Stromal TumoursGonadoblastomaGerm cell-sex cord/gonadal stromal tumour, unclassifiedMiscellaneous tumours of the testisCarcinoidTumours of ovarian epithelial typesSerous tumour of borderline malignancySerous carcinomaWell differentiated endometrioid tumourMucinous cystadenomaMucinous cystadenocarcinomaBrenner tumourNephroblastomaParagangliomaHaematopoietic tumoursTumours of collecting ducts and reteAdenomaCarcinomaTumours of the paratesticular structuresAdenomatoid tumourMalignant and Benign MesotheliomaAdenocarcinoma of the epididymisPapillary cystadenoma of the epididymisMelanotic neuroectodermal tumourDesmoplastic small round cell tumourMesenchymal tumours of the spermatic cord and testicular adnexaeLipomaLiposarcomaRhabdomyosarcomaAggressive angiomyxomaAngiomyofibroblastoma-like tumour (see Myxoma)FibromatosisFibromaSolitary fibrous tumourOthersSecondary tumours of the testisTreatmentThe three basic types of treatment are surgery, radiation therapy, and chemotherapy. Surgery is performed by urologists; radiation therapy is administered by radiation oncologists; and chemotherapy is the work of medical oncologists. In most patients with testicular cancer, the disease is cured readily with minimal long-term morbidity. While treatment success depends on the stage, the average survival rate after five years is around 95%, and stage 1 cancers cases (if monitored properly) have essentially a 100% survival rate (which is why prompt action, when testicular cancer is a possibility, is extremely important). Initial treatment (orchiectomy)Main article: OrchiectomySee also: MonorchismThe initial treatment for testicular cancer is surgery to remove the affected testicle (orchiectomy). While it may be possible, in some cases, to remove testicular cancer tumors from a testis while leaving the testis functional, this is almost never done, as the affected testicle usually contains pre-cancerous cells spread throughout the entire testicle. Thus removing the tumor alone without additional treatment greatly increases the risk that another cancer will form in that testicle. Since only one testis is typically required to maintain fertility, hormone production, and other male functions, the afflicted testis is almost always removed completely in a procedure called inguinal orchiectomy. (The testicle is almost never removed through the scrotum; an incision is made beneath the belt line in the inguinal area.) In the UK, the procedure is known as a radical orchidectomy. Retroperitoneal Lymph Node Dissection (RPLND)In the case of nonseminomas that appear to be stage I, surgery may be done on the retroperitoneal/Paraaortic lymph nodes (in a separate operation) to accurately determine whether the cancer is in stage I or stage II and to reduce the risk that malignant testicular cancer cells that may have metastasized to lymph nodes in the lower abdomen. This surgery is called retroperitoneal lymph node dissection (RPLND). However, this approach, while standard in many places, especially the United States, is out of favor due to costs and the high level of expertise required to perform successful surgery. Sperm banking is frequently carried out prior to the procedure (as with chemotherapy), as there is a risk that RPLND may damage the nerves involved in ejaculation, causing ejaculation to occur internally into the bladder rather than externally. Many patients are instead choosing surveillance, where no further surgery is performed unless tests indicate that the cancer has returned. This approach maintains a high cure rate because of the growing accuracy of surveillance techniques. Adjuvant treatmentSince testicular cancers can spread, patients are usually offered adjuvant treatment - in the form of chemotherapy or radiotherapy - to kill any cancerous cells that may exist outside of the affected testicle. The type of adjuvant therapy depends largely on the histology of the tumor (i.e. the size and shape of its cells under the microscope) and the stage of progression at the time of surgery (i.e. how far cells has 'escaped' from the testicle, invaded the surrounding tissue, or spread to the rest of the body). If the cancer is not particularly advanced, patients may be offered careful surveillance by periodic CT scans and blood tests, in place of adjuvant treatment. Before 1970, survival rates from testicular cancer were low. Since the introduction of adjuvant chemotherapy, chiefly platinum-based drugs like cisplatin and carboplatin, the outlook has improved substantially. Although 7000 to 8000 new cases of testicular cancer occur in the United States yearly, only 400 men are expected to die of the disease. In the UK, a similar trend has emerged: since improvements in treatment, survival rates have risen rapidly to cure rates of over 95%. Radiation therapyRadiation may be used to treat stage 2 seminoma cancers, or as adjuvant (preventative) therapy in the case of stage 1 seminomas, to minimize the likelihood that tiny, non-detectable tumors exist and will spread (in the inguinal and para-aortic lymph nodes). Radiation is ineffective against and is therefore never used as a primary therapy for nonseminoma. ChemotherapyNon-seminomaChemotherapy is the standard treatment for non-seminoma when the cancer has spread to other parts of the body (that is, stage 2B or 3). The standard chemotherapy protocol is three, or sometimes four, rounds of Bleomycin-Etoposide-Cisplatin (BEP). BEP as a first-line treatment was first reported by Professor Michael Peckham in 1983. The landmark trial published in 1987 which established BEP as the optimum treatment was conducted by Dr. Lawrence Einhorn at Indiana University. An alternative, equally effective treatment involves the use of four cycles of Etoposide-Cisplatin (EP). Lymph node surgery may also be performed after chemotherapy to remove masses left behind (stage 2B or more advanced), particularly in the cases of large nonseminomas. SeminomaAs an adjuvant treatment, use of chemotherapy as an alternative to radiation therapy in the treatment of seminoma is increasing, because radiation therapy appears to have more significant long-term side effects (for example, internal scarring, increased risks of secondary malignancies, etc.). Two doses, or occasionally a single dose of carboplatin, typically delivered three weeks apart, is proving to be a successful adjuvant treatment, with recurrence rates in the same ranges as those of radiotherapy. The concept of carboplatin as a single-dose therapy was developed by Tim Oliver, Professor of Medical Oncology at Barts and The London School of Medicine and Dentistry. However, very long term data on the efficacy of adjuvant carboplatin in this setting do not exist. Since seminoma can recur decades after the primary tumor is removed, patients receiving adjuvant chemotherapy should remain vigilant and not assume they are cured 5 years after treatment. PrognosisIn the New England Journal of Medicine in 2008, treatment of testicular cancer was called one of the success stories of modern medicine, with sustained response to treatment in more than 90% of cases, regardless of stage. In 2011 overall cure rates of more than 95% were reported, and 80% for metastatic disease—the best response by any solid tumor, with improved survival being attributed primarily to effective chemotherapy. By 2013, according to Cancer Research UK, more than 96 per cent of the 2,300 men diagnosed each year in the U.K. were deemed cured, a rise by almost a third since the 1970s, the improvement attributed substantially to the chemotherapy drug cisplatin. SurveillanceFor many patients with stage I cancer, adjuvant (preventative) therapy following surgery may not be appropriate and patients will undergo surveillance instead. The form this surveillance takes, e.g. the type and frequency of investigations and the length time it should continue, will depend on the type of cancer (non-seminoma or seminoma), but the aim is to avoid unnecessary treatments in the many patients who are cured by their surgery, and ensure that any relapses with metastases (secondary cancers) are detected early and cured. This approach ensures that chemotherapy and or radiotherapy is only given to the patients that need it. The number of patients ultimately cured is the same using surveillance as post-operative “adjuvant” treatments, but the patients have to be prepared to follow a prolonged series of visits and tests. For both non-seminomas and seminomas, surveillance tests generally include physical examination, blood tests for tumour markers, chest x-rays and CT scanning. However, the requirements of a surveillance programme differ according to the type of disease since, for seminoma patients, relapses can occur later and blood tests are not as good at indicating relapse. CT scans are performed on the abdomen (and sometimes the pelvis) and also the chest in some hospitals. Chest x-rays are increasingly preferred for the lungs as they give sufficient detail combined with a lower false-positive rate and significantly smaller radiation dose than CT. The frequency of CT scans during surveillance should ensure that relapses are detected at an early stage while minimising the radiation exposure. For patients treated for stage I non-seminoma, a randomised trial (Medical Research Council TE08) showed that, when combined with the standard surveillance tests described above, 2 CT scans at 3 and 12 months were as good as 5 over 2 years in detecting relapse at an early stage. For patients treated for stage I seminoma who choose surveillance rather than undergoing adjuvant therapy, there have been no randomised trials to determine the optimum frequency of scans and visits, and the schedules vary very widely across the world, and within individual countries. In the UK there is an ongoing clinical trial called TRISST. This is assessing how often scans should take place and whether magnetic resonance imaging (MRI) can be used instead of CT scans. MRI is being investigated because it does not expose the patient to radiation and so, if it is shown to be as good at detecting relapses, it may be preferable to CT. It is possible that one or more centres in Canada may join the trial in the next year or so. For more advanced stages of testicular cancer, and for those cases in which radiation therapy or chemotherapy was administered, the extent of monitoring (tests) after treatment will vary on the basis of the circumstances, but normally should be done for five years in uncomplicated cases and for longer in those with higher risks of relapse. FertilityA man with one remaining testis may maintain fertility. However, sperm banking may be appropriate for men who still plan to have children, since fertility may be adversely affected by chemotherapy and/or radiotherapy. A man who loses both testicles will be infertile. EpidemiologyGlobally, as of 2010, testicular cancer resulted in about 8,000 deaths. Testicular cancer is most common among Caucasian men and rare among men of African descent. Testicular cancer is uncommon in Asia and Africa. Worldwide incidence has doubled since the 1960s, with the highest rates of prevalence in Scandinavia, Germany, and New Zealand. Higher rates of testicular cancer in western nations have been linked to use of cannabis. A study conducted by the Fred Hutchinson Cancer Research Center and funded by the National Institutes of Health, published in the journal Cancer March 15, 2009, linked long term use of cannabis to an increased risk for testicular cancer with the scientists concluding that cannabis is harmful to the human endocrine and reproductive system. In September 2012, a study published in the journal Cancer became the third to link marijuana use to the development of testicular cancer. Incidence among African Americans doubled from 1988 to 2001 with a bias towards seminoma. The lack of significant increase in the incidence of early-stage testicular cancer during this timeframe suggests that the overall increase was not due to heightened awareness of the disease. Although testicular cancer is most common among men aged 15–40 years, it has three peaks: infancy through the age of four as teratomas and yolk sac tumors, ages 25–40 years as post-pubertal seminomas and nonseminomas, and from age 60 as spermatocytic seminomas. Germ cell tumors of the testis are the most common cancer in young men between the ages of 15 and 35 years. A major risk factor for the development of testis cancer is cryptorchidism (undescended testicles). It is generally believed that the presence of a tumor contributes to cryptorchidism; when cryptorchidism occurs in conjunction with a tumor then the tumor tends to be large. Other risk factors include inguinal hernias, Klinefelter syndrome, and mumps orchitis.  Physical activity is associated with decreased risk and sedentary lifestyle is associated with increased risk. Early onset of male characteristics is associated with increased risk. These may reflect endogenous or environmental hormones.